In this time of dire need, Sepragen team is doing its part to solve the problem of COVID-19. We are providing equipment on an expedited basis to a company developing a vaccine for COVID- 19.
Biologic Drug Manufacturing

Biologic Drug Manufacturing

Sepragen has pioneered the three patented processes for the isolation of high value nutritionals on a commercial scale. The Sepralac® Process enables the isolation of high value whey protein isolate, alphalactalbumin, lactoferrin and CGMP for use in infant formulae, performance foods and other functional foods. Commercial plants capable of processing over 100,000 liters of whey per day have been commissioned. Sepradebitt® process to debitter and de-acify citrus juice and the Sepraflavone® Process to isolate the natural “phyto” estrogen of Isoflavone from soy are currently in commercial evaluations with potential licenses.
news
You may also like
Browse All
January 2023
Sepragen ships
In the creation of bio-pharmaceutical drugs, cells are genetically modified to produce some compound shown by research to have a desired effect in a treatment program.
Learn more
December 2022
Sepragen completes installation
Sepragen’s products or tools are used to manufacture over 24 FDA approved drugs including Kogenate®, Alphanate®, Neupogen®, and GammaGrand®* along with a multitude...
Learn more
July 2022
Sepragen presents at the Recovery Conference in Rome
Sepragen has pioneered the three patented processes for the isolation of high value nutritionals on a commercial scale. The Sepralac® Process enables the isolation of Lactoferrin...
Learn more